ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "S3E11 - What is Factor parallelism for?"
Episode Synopsis
Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today’s episode, our guest Tom Childs will help us to understand the goal and clinical benefits of the Factor parallelism method.
Link to previous podcasts:
S1E11 – How to be more productive (part 1): implementation of a rules enginehttps://www.podcastics.com/podcast/episode/10-how-to-be-more-productive-part-1-implementation-of-a-rules-engine-37749/
S2E8 - World Hemophilia Dayhttps://www.podcastics.com/podcast/episode/s2e8-world-hemophilia-day-72341/
S2E4 - How to determine factor levels in hemophilia?https://www.podcastics.com/podcast/episode/s2e4-how-to-determine-factor-levels-in-hemophilia-62593/
Literature sources:
Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program 2006: 432–7 (https://ashpublications.org/hematology/article/2006/1/432/19703/Acquired-Factor-VIII-Inhibitors-Pathophysiology).
Morfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008; 14 (Suppl 6): 20–2.
Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (7): 2358–63
Monahan PE, Baker JR, Riske B, Soucie JM. Physical functioning in boys with hemophilia in the U.S. Am J Prev Med 2011; 41 (6 Suppl 4): S360–8.
Collins PW, Chalmers E, Hart D et al.; United Kingdom Haemophilia Centre Doctors’ Organization. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol 2013; 162 (6): 758–73 (https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.12463).
Riley PW, Gallea B, Valcour A. Development and implementation of a coagulation factor testing method utilizing autoverification in a high‑volume clinical reference laboratory environment. J Pathol Inform 2017; 8: 25.
Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4 (1): 59–72
Oldenburg J, Mahlangu JN, Kim B et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (9): 809–18.
Florin L, Desloovere M, Devreese KML. Validation of an automated algorithm for interpretation of lupus anticoagulant testing on the Stago STA R Max (Poster). International Society on Thrombosis and Haemostasis, 2017.
Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.
Link to previous podcasts:
S1E11 – How to be more productive (part 1): implementation of a rules enginehttps://www.podcastics.com/podcast/episode/10-how-to-be-more-productive-part-1-implementation-of-a-rules-engine-37749/
S2E8 - World Hemophilia Dayhttps://www.podcastics.com/podcast/episode/s2e8-world-hemophilia-day-72341/
S2E4 - How to determine factor levels in hemophilia?https://www.podcastics.com/podcast/episode/s2e4-how-to-determine-factor-levels-in-hemophilia-62593/
Literature sources:
Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program 2006: 432–7 (https://ashpublications.org/hematology/article/2006/1/432/19703/Acquired-Factor-VIII-Inhibitors-Pathophysiology).
Morfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008; 14 (Suppl 6): 20–2.
Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (7): 2358–63
Monahan PE, Baker JR, Riske B, Soucie JM. Physical functioning in boys with hemophilia in the U.S. Am J Prev Med 2011; 41 (6 Suppl 4): S360–8.
Collins PW, Chalmers E, Hart D et al.; United Kingdom Haemophilia Centre Doctors’ Organization. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol 2013; 162 (6): 758–73 (https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.12463).
Riley PW, Gallea B, Valcour A. Development and implementation of a coagulation factor testing method utilizing autoverification in a high‑volume clinical reference laboratory environment. J Pathol Inform 2017; 8: 25.
Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4 (1): 59–72
Oldenburg J, Mahlangu JN, Kim B et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (9): 809–18.
Florin L, Desloovere M, Devreese KML. Validation of an automated algorithm for interpretation of lupus anticoagulant testing on the Stago STA R Max (Poster). International Society on Thrombosis and Haemostasis, 2017.
Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.
More episodes of the podcast Ask Stago (english version)
S5E8 - Anti Xa and UFH monitoring
26/06/2025
S5E2 - Living with a rare blood clotting disorder, Hemophilia C: an interview with Joseph Bautista
07/05/2024
S5E1 - What is new in ISO 15189:2022?
02/04/2024
S4E4 - Limit of detection (LoD) and limit of quantitation (LoQ): what are we talking about?
23/05/2023
S4E3 - Women at work and Women in Science
07/03/2023
In God we trust